MCID: CRB039
MIFTS: 70

Cerebrovascular Disease

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 56 15
Cerebrovascular Disorders 45 74
Cerebrovascular Accident 12 74
Cerebrovascular Disorder 12 17
Stroke 12 45
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
NCIt 51 C2938 C3390
SNOMED-CT 69 62914000 82797006

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to peripheral artery disease and stroke, ischemic, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Microglia Activation During Neuroinflammation: Overview. The drugs Rivastigmine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 77 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1485)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.6 ACE APOB CRP SELP
2 stroke, ischemic 32.4 ACE AGTR1 APOB APOE CRP MTHFR
3 cerebral palsy 32.4 APOE COL4A1 MTHFR
4 grange syndrome 32.3 MTHFR PLAT SELP
5 vascular dementia 32.3 ACE ACHE APOE APP MTHFR NOTCH3
6 binswanger's disease 32.2 ACHE APOE APP NOTCH3
7 supranuclear palsy, progressive, 1 32.2 ACHE APOE APP
8 dementia 31.5 ACHE APOE APP NOTCH3
9 cerebral atherosclerosis 31.5 ACE APOA1 APOE MTHFR
10 cerebral amyloid angiopathy, cst3-related 31.5 APOE APP SERPINA3
11 arteriosclerosis 31.4 ACE ADM APOA1 APOB APOE CRP
12 sleep apnea 31.0 ACE APOE CRP
13 carotid stenosis 30.9 ACE APOE CRP MTHFR SELP
14 aortic atherosclerosis 30.7 ACE APOE PON1
15 hemorrhage, intracerebral 30.7 ACE APOE APP COL4A1 PLAT
16 ischemic heart disease 30.6 ACE AGTR1 APOA1 APOB APOE CRP
17 ischemia 30.6 ACE APP PLAT PON1 SELP
18 platelet aggregation, spontaneous 30.6 PLAT SELP SERPINA3
19 atherosclerosis susceptibility 30.6 APOA1 APOB APOE CRP PON1
20 homocysteinemia 30.5 CRP MTHFR MTR
21 peripheral vascular disease 30.5 ACE APOA1 APOB CRP PLAT SELP
22 atrial fibrillation 30.5 ACE AGTR1 CRP PLAT SELP
23 pulmonary embolism 30.5 CRP MTHFR PLAT
24 macular degeneration, age-related, 1 30.5 APOB APOE CRP CX3CR1
25 arteries, anomalies of 30.5 ACE AGTR1 APOA1 APOB APOE CRP
26 ischemic optic neuropathy 30.4 ACE AGTR1 MTHFR
27 coronary artery anomaly 30.4 ACE AGTR1 APOA1 APOB CRP PLAT
28 angina pectoris 30.4 ACE CRP PLAT
29 antiphospholipid syndrome 30.4 MTHFR PLAT SELP
30 nonarteritic anterior ischemic optic neuropathy 30.3 ACE AGTR1 MTHFR
31 coronary heart disease 1 30.3 ACE APOA1 APOB APOE CRP CX3CR1
32 carotid artery disease 30.3 ACE APOA1 APOB APOE CRP
33 vitamin b12 deficiency 30.3 MTHFR MTR PON1
34 cerebral hemorrhage 30.3 APOB APP
35 migraine with aura 30.3 ACE MTHFR NOTCH3
36 intermittent claudication 30.2 ACE CRP SELP
37 renal hypertension 30.1 ACE ADM AGTR1
38 renovascular hypertension 30.1 ACE ADM AGTR1
39 hypertriglyceridemia, familial 30.1 APOA1 APOB APOE
40 carotid artery dissection 30.1 HOTAIR MTHFR PLAT
41 systemic scleroderma 30.1 ACE CRP SELP
42 microvascular complications of diabetes 5 30.1 ACE AGTR1 PON1
43 diabetes mellitus, noninsulin-dependent 30.1 ACE AGTR1 APOA1 APOB APOE CRP
44 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 30.1 MTHFR MTR
45 coronary stenosis 30.0 ACE APOA1 APOB APOE CRP PON1
46 alzheimer's disease 1 30.0 APOE APP
47 end stage renal failure 30.0 ACE AGTR1 APOB CRP
48 dementia, lewy body 30.0 ACHE APOE APP
49 nephrosclerosis 30.0 ACE AGTR1 MTHFR
50 lipid metabolism disorder 30.0 ACE APOA1 APOB APOE CRP

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures, tremor, angina pectoris, edema, back pain, pain, headache, chest pain, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness, transient ischemic attacks, stereotypic symptoms

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 ACE ACHE ADM AGTR1 APOA1 APOB
2 cardiovascular system MP:0005385 10.39 ACE ADM AGTR1 APOA1 APOB APOE
3 behavior/neurological MP:0005386 10.3 ACE ACHE ADM AGTR1 APOE APP
4 growth/size/body region MP:0005378 10.3 ACE ACHE AGTR1 APOB APOE APP
5 cellular MP:0005384 10.28 ADM APOA1 APOB APOE APP COL4A1
6 immune system MP:0005387 10.26 ACE ADM AGTR1 APOB APOE APP
7 hematopoietic system MP:0005397 10.25 ACE ACHE ADM AGTR1 APOE APP
8 mortality/aging MP:0010768 10.25 ACE ACHE ADM AGTR1 APOB APOE
9 integument MP:0010771 10.11 ADM APOA1 APOE APP CX3CR1 MTHFR
10 nervous system MP:0003631 10.06 ACHE AGTR1 APOB APOE APP COL4A1
11 muscle MP:0005369 10.02 ACHE ADM APOB APOE APP COL4A1
12 liver/biliary system MP:0005370 9.98 ACE ADM APOA1 APOB APOE MTHFR
13 reproductive system MP:0005389 9.9 ACE ACHE ADM APOB APOE APP
14 renal/urinary system MP:0005367 9.86 ACE ADM AGTR1 APOE COL4A1 CX3CR1
15 respiratory system MP:0005388 9.5 ACHE ADM APOE COL4A1 NOTCH3 PLAT
16 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 921)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
3
Amiloride Approved Phase 4 2609-46-3, 2016-88-8 16231
4
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
5
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
6
Telmisartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144701-48-4 65999
7
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
8
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
9
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
10
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 53123-88-9 46835353 5284616 6436030
11
Everolimus Approved Phase 4,Phase 2,Phase 3,Not Applicable 159351-69-6 70789204 6442177
12
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 73963-72-1 2754
13
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 134523-00-5 60823
14
Perindopril Approved Phase 4,Phase 3,Not Applicable 107133-36-8, 82834-16-0 107807
15
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-93-5 3639
16
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
17
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
19
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 124-94-7 31307
21
Rivaroxaban Approved Phase 4,Phase 2,Phase 3,Not Applicable 366789-02-8
22
Valsartan Approved, Investigational Phase 4,Phase 2,Not Applicable 137862-53-4 60846
23
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
24
Nadroparin Approved, Investigational Phase 4,Phase 3
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 46507594 772
26
Probucol Approved, Investigational Phase 4 23288-49-5 4912
27
Nimodipine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 66085-59-4 4497
28
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
31
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Not Applicable 152-72-7 54676537 9052
32
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
33
Nicardipine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55985-32-5 4474
34
alemtuzumab Approved, Investigational Phase 4 216503-57-0
35
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
36
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
37
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
38
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
39
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
40
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 120014-06-4 3152
41
Bupropion Approved Phase 4,Not Applicable 34841-39-9, 34911-55-2 444
42
Varenicline Approved, Investigational Phase 4,Not Applicable 249296-44-4 5310966
43
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
44
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 5311068 68602
45
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
46
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
47
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 54678486 6691
48
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-41-2 439260
49
Galantamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 357-70-0 9651
50
Edaravone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 89-25-8 70335

Interventional clinical trials:

(show top 50) (show all 5195)
# Name Status NCT ID Phase Drugs
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
4 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
5 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
6 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
7 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
8 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
9 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Unknown status NCT02594995 Phase 4 NBP
10 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
11 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
12 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
13 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
14 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
15 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
16 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
17 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Unknown status NCT01932203 Phase 4 aspirin;cilostazol
18 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
19 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
20 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
21 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
22 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
23 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
24 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
25 Preventive Effects of Ginseng Against Atherosclerosis Unknown status NCT02796664 Phase 4
26 Botulinum Toxin A for Shoulder Pain After Stroke Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
27 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
28 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
29 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
30 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
31 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
32 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
33 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
34 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
35 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
36 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
37 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
38 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
39 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
40 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
41 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
42 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
43 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
44 Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Unknown status NCT02224209 Phase 4
45 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
46 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
47 Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy Unknown status NCT01918722 Phase 4 ICH-1(herbal medicine with Hirudo, Tabanus);placebo;ICH-2(herbal medicine without Hirudo, Tabanus)
48 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol
49 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
50 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population Unknown status NCT02618382 Phase 4 Tranexamic Acid

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

42
Brain, Heart, Testes, Bone, Kidney, Endothelial, Liver

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 2981)
# Title Authors Year
1
Cognitive deterioration in schizophrenia: aging and cerebrovascular disease. ( 29936917 )
2019
2
Five-year incidence of common comorbidities, such as hypertension, dyslipidemia, diabetes mellitus, cardiovascular disease, cerebrovascular disease and cancer, in older Japanese patients with rheumatoid arthritis. ( 30950139 )
2019
3
Lifetime discrimination burden, racial discrimination, and subclinical cerebrovascular disease among African Americans. ( 30474995 )
2019
4
Circulating inflammatory biomarkers are related to cerebrovascular disease in older adults. ( 30568999 )
2019
5
Cost-effectiveness of home blood pressure telemonitoring and case management in the secondary prevention of cerebrovascular disease in Canada. ( 30570200 )
2019
6
The relationship between obesity subtypes based on BMI and cardio-cerebrovascular disease. ( 30622319 )
2019
7
Four-Year Experience Using an Advanced Interdisciplinary Hybrid Operating Room : Potentials in Treatment of Cerebrovascular Disease. ( 30630294 )
2019
8
Bell Palsy and the Risk of Cardio-Cerebrovascular Disease: A Population-Based Follow-Up Study. ( 30632167 )
2019
9
Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®. ( 30648358 )
2019
10
Night-time systolic blood pressure and subclinical cerebrovascular disease: the Cardiovascular Abnormalities and Brain Lesions (CABL) study. ( 30649236 )
2019
11
Effect of Interventional Therapy on IL-1β, IL-6, and Neutrophil-Lymphocyte Ratio (NLR) Levels and Outcomes in Patients with Ischemic Cerebrovascular Disease. ( 30664615 )
2019
12
Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: A case report. ( 30680201 )
2019
13
High cholesterol triggers white matter alterations and cognitive deficits in a mouse model of cerebrovascular disease: benefits of simvastatin. ( 30692517 )
2019
14
Cerebrovascular Disease: Primary and Secondary Stroke Prevention. ( 30704682 )
2019
15
Clinical factors influencing the development of extracranial-intracranial bypass graft for steno-occlusive cerebrovascular disease. ( 30717071 )
2019
16
Patients with Acute Ischemic Cerebrovascular Disease with Coronary Artery Stenosis Have More Diffused Cervicocephalic Atherosclerosis. ( 30726790 )
2019
17
Mixed cerebrovascular disease in an elderly patient with mixed vascular risk factors: a case report. ( 30755166 )
2019
18
Cerebrovascular disease burden in late-onset non-lesional focal epilepsy. ( 30776698 )
2019
19
Commentary on "Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study". ( 30777638 )
2019
20
Cerebrovascular Disease in the Young Adult: Examining Melatonin's Possible Multiple Roles. ( 30783379 )
2019
21
Serum klotho: a potential predictor of cerebrovascular disease in hemodialysis patients. ( 30791885 )
2019
22
Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel. ( 30817601 )
2019
23
A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma. ( 30825967 )
2019
24
Assessment of physical activity and cognitive function and their potential correlation in convalescent patients of cerebrovascular disease. ( 30846760 )
2019
25
Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome. ( 30864116 )
2019
26
mTOR in neurological diseases. ( 30867339 )
2019
27
A U-Net Deep Learning Framework for High Performance Vessel Segmentation in Patients With Cerebrovascular Disease. ( 30872986 )
2019
28
Associations of plasma LP(a), Hcy and D-D levels with the subtype of ischemic cerebrovascular disease. ( 30882710 )
2019
29
Association between gallstone and cardio-cerebrovascular disease: Systematic review and meta-analysis. ( 30936980 )
2019
30
Cortical Venous Reddening Predicts Remote Cerebral Infarction Post Superficial Temporal Artery-Middle Cerebral Artery Bypass in Atherosclerotic Occlusive Cerebrovascular Disease. ( 30954735 )
2019
31
Predicting asymptomatic coronary artery stenosis by aortic arch plaque in acute ischemic cerebrovascular disease: beyond the cervicocephalic atherosclerosis? ( 30958431 )
2019
32
Increased incidence of ischaemic heart disease and cerebrovascular disease in psoriasis patients with depression: a nationwide retrospective cohort study. ( 30977931 )
2019
33
Association between excessive supraventricular ectopy and subclinical cerebrovascular disease: A population-based study. ( 31002446 )
2019
34
The Burden of Cerebrovascular Disease in the United States. ( 31022369 )
2019
35
Prevalence and vascular risk factors of basal ganglia calcifications in patients at risk for cerebrovascular disease. ( 31034898 )
2019
36
Reconsideration of three screening tests for dysphagia in patients with cerebrovascular disease performed by non-expert examiners. ( 31037446 )
2019
37
Simultaneous phase-contrast MRI and PET for noninvasive quantification of cerebral blood flow and reactivity in healthy subjects and patients with cerebrovascular disease. ( 31044459 )
2019
38
Attention to acute cerebrovascular disease in Guipúzcoa: Description of the results of a reference hospital in a centralized care model. ( 31053483 )
2019
39
Preeclampsia and Cerebrovascular Disease. ( 31055951 )
2019
40
Matrix metalloproteinases as target genes for gene regulatory networks driving molecular and cellular pathways related to a multistep pathogenesis of cerebrovascular disease. ( 31056794 )
2019
41
Diagnostic and prognostic values of cerebral oxygen saturations measured by INVOS™ in patients with ischemic and hemorrhagic cerebrovascular disease. ( 31073543 )
2019
42
Non-fasting triglyceride levels in the Korean population with and without ischemic heart disease and cerebrovascular disease. ( 29132199 )
2019
43
Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease. ( 30042112 )
2019
44
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( 30100558 )
2019
45
Epidemiology report: trends in sex-specific cerebrovascular disease mortality in Europe based on WHO mortality data. ( 30124820 )
2019
46
Autonomic Disturbances in Acute Cerebrovascular Disease. ( 30311072 )
2019
47
APOE genotypes as a risk factor for age-dependent accumulation of cerebrovascular disease in older adults. ( 30321502 )
2019
48
Repurposing of Approved Cardiovascular Drugs against Ischemic Cerebrovascular Disease by Disease-Disease Associated Network-Assisted Prediction. ( 30404981 )
2019
49
Long-term impact of critical silent cerebrovascular disease in patients undergoing coronary artery bypass surgery: a propensity score and multivariate analyses. ( 30444180 )
2019
50
Cerebrovascular disorders associated with genetic lesions. ( 30327838 )
2019

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 APOA1 APOB APOE MTHFR MTR
2
Show member pathways
11.72 APP COL4A1 CX3CR1 PLAT
3
Show member pathways
11.57 APOA1 APOB APOE COL4A1
4
Show member pathways
11.56 APOA1 APOB APOE CRP MTHFR MTR
5 11.23 APOB PLAT SELP
6 10.76 ACE APOE APP CX3CR1
7 10.69 ACE APP PLAT
8 10.51 HOTAIR MEG3

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.88 APOA1 APOB APOE APP COL4A1
2 collagen-containing extracellular matrix GO:0062023 9.85 APOA1 APOE COL4A1 PLAT SERPINA3
3 early endosome GO:0005769 9.84 APOA1 APOB APOE APP
4 blood microparticle GO:0072562 9.81 APOA1 APOE PON1 SERPINA3
5 extracellular region GO:0005576 9.77 ACE ACHE ADM APOA1 APOB APOE
6 high-density lipoprotein particle GO:0034364 9.61 APOA1 APOE PON1
7 very-low-density lipoprotein particle GO:0034361 9.58 APOA1 APOB APOE
8 endosome lumen GO:0031904 9.56 APOB APP
9 synaptic cleft GO:0043083 9.55 ACHE APOE
10 endocytic vesicle lumen GO:0071682 9.54 APOA1 APOB APOE
11 spherical high-density lipoprotein particle GO:0034366 9.52 APOA1 PON1
12 low-density lipoprotein particle GO:0034362 9.5 APOA1 APOB APOE
13 discoidal high-density lipoprotein particle GO:0034365 9.49 APOA1 APOE
14 extracellular space GO:0005615 9.44 ACE ACHE ADM APOA1 APOB APOE
15 chylomicron GO:0042627 9.43 APOA1 APOB APOE
16 intermediate-density lipoprotein particle GO:0034363 9.33 APOA1 APOB APOE

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.9 APOA1 APOB APOE APP
2 cholesterol homeostasis GO:0042632 9.82 APOA1 APOB APOE
3 platelet degranulation GO:0002576 9.81 APOA1 APP SELP SERPINA3
4 response to wounding GO:0009611 9.79 ACHE ADM CX3CR1
5 retinoid metabolic process GO:0001523 9.74 APOA1 APOB APOE
6 triglyceride catabolic process GO:0019433 9.67 APOA1 APOB APOE
7 high-density lipoprotein particle remodeling GO:0034375 9.66 APOA1 APOE
8 positive regulation of lipid biosynthetic process GO:0046889 9.66 APOA1 APOE
9 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.65 AGTR1 APOB
10 positive regulation of cholesterol efflux GO:0010875 9.65 APOE PON1
11 regulation of blood vessel diameter GO:0097746 9.65 ACE AGTR1
12 cholesterol efflux GO:0033344 9.65 APOA1 APOB APOE
13 high-density lipoprotein particle assembly GO:0034380 9.64 APOA1 APOE
14 phospholipid efflux GO:0033700 9.63 APOA1 APOE
15 amyloid precursor protein metabolic process GO:0042982 9.63 ACHE APOE
16 lipoprotein metabolic process GO:0042157 9.63 APOA1 APOB APOE
17 methionine biosynthetic process GO:0009086 9.62 MTHFR MTR
18 high-density lipoprotein particle clearance GO:0034384 9.62 APOA1 APOE
19 very-low-density lipoprotein particle remodeling GO:0034372 9.61 APOA1 APOE
20 artery morphogenesis GO:0048844 9.61 APOB APOE NOTCH3
21 chylomicron remnant clearance GO:0034382 9.59 APOB APOE
22 regulation of Cdc42 protein signal transduction GO:0032489 9.58 APOA1 APOE
23 regulation of cholesterol transport GO:0032374 9.58 APOA1 APOE
24 low-density lipoprotein particle remodeling GO:0034374 9.58 AGTR1 APOB APOE
25 regulation of systemic arterial blood pressure by renin-angiotensin